newsfilter
← Latest News
Business Wire·

FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy

Priority review decision is based on Phase III MAJESTY results, where Gazyva achieved significantly higher complete remission rates at two years compared to tacrolimus If approved, Gazyva will be the first